The global Hashimoto’s Thyroiditis Diagnosis and Treatment Market is anticipated to grow at a considerable CAGR during the forecast period (2021-2027). The key factor to drive the market growth is the increasing prevalence of hypothyroidism among the population. For instance, Hashimoto thyroiditis also known as lymphocytic thyroiditis is the major cause of hypothyroidism in the US where it is mostly seen in women in the region. According to the American Thyroid Association, it has been estimated that around 12.0% of Americans will be developing thyroid conditions in their lifetime in which almost 20 million Americans already have some form of thyroid disease. 60.0% of the US population with thyroid disorder are not aware of their condition. Various government organizations such as the American Thyroid Association, the British Thyroid Foundation, Thyroid Foundation of Canada partnering with many major corporate players for increasing awareness about the diseases and treatment options. For instance, the American Thyroid Association exhibits partnerships with major players such as AbbVie, Horizon, Takeda International, and others. With the help of the corporate leadership council with its partners, it enables open communication between the ATA and the community of corporations about thyroid health.
Browse the full report description of "Global Hashimoto’s Thyroiditis Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Thyroid-Stimulating Hormone Test, Thyroxine Test, Antithyroid Antibody Test), By Treatment (Levothyroxine, Triiodothyronine, Desiccated Thyroid Extract and other), Distribution Channel (Hospital Pharmacies, and Retail Pharmacies) Forecast Period 2021-2027" at https://www.omrglobal.com/industry-reports/hashimotos-thyroiditis-diagnosis-and-treatment-market
Rising acquisitions, collaborations among the major players in the market also propel the growth of the market. For instance, in March 2021, Merk a US-based pharma giant acquired Pandion Therapeutics for its TALON technology and immune modulators. Merk acquired Pandion for $1.85 billion and the strategy behind this acquisition was to address the unmet needs of patients suffering from autoimmune diseases. With this acquisition, Merk will be creating a pipeline of diverse candidates that will be activating the natural immune regulatory mechanisms and have chances of achieving better clinical responses for patients with such diseases.
Market Coverage
o By Diagnosis
o By Treatment
o By Distribution Channel
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Hashimoto’s Thyroiditis Diagnosis and Treatment Market Report Segment
By Diagnosis
By Treatment
By Distribution Channel
Global Hashimoto’s Thyroiditis Diagnosis and Treatment Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hashimotos-thyroiditis-diagnosis-and-treatment-market